Announcement on Abnormal Fluctuations in Stock Trading
Filed with SSE · · 3 pages · Chinese
Earlier from BeOne Medicines
- BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
- BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
- BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
- Announcement on Convening the 2025 Semi-annual Performance Briefing
Later from BeOne Medicines
- Announcement on Progress in Litigation Involving the Company
- BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
- BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
- BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
- BeOne Medicines to Present at Upcoming Investor Conferences
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines